DTP Branches and Offices
Last Updated: 04/08/15
Other Programs of Interest
- NCI Experimental Therapeutics Program (NExT)
Application Receipt Dates: November 15, February 15, May 15 and August 15 - Chemical Biology Consorium (CBC): A new program in DCTD designed to accelerate discovery and development of effective first-in-class targeted therapies. Check the DCTD web site for current opportunities.
- Quick Trials: A funding mechanism through the Cancer Therapy Evaluation Program to support pilot clinical trials exploring individual agents or combinations focused on specific molecular targets.
Helpful Related Links
- National Cancer Institute Program Project (PO1) Applications
- New NIH Policy on Resubmission (Amended) Applications
- Writing or renewing an NIH grant application? After Jan. 1, 2009, SF424 R&R forms require specific versions of Adobe Reader to ensure the forms work properly. Incorrect version may prevent successful submission of your application to Grants.gov. See NIH’s eSubmission Web site for more information.
- Guidance on Natural Disasters in regard to grant application submissions
- Encourage Early Transition to Research Independence: Modifying the NIH New Investigator Policy to Identify Early Stage Investigators (NOT-OD-08-121) National Institutes of Health
- Announcing Transition Schedule for NIH/AHRQ/NIOSH/FDA to Adobe-based Forms for SF424 Research and Related (R&R) Electronic Submissions through Grants.gov (NOT-OD-08-117) National Institutes of Health/Agency for Healthcare Research and Quality/Center for Disease Control and Prevention/National Institute for Occupations Safety and Health
- Reminder Concerning Grantee Compliance with Public Access Policy adn Related NIH Monitoring Activites (NOT-OD-08-119) National Institutes of Health
- Coming Changes in the Peer Review of Grant Applications
- Change in Standing Receipt Dates for NIH/AHRQ/NIOSH Beginning in January 2007 (NOT-OD-07-001)
- Resources for New Investigators
- NIH Policy on Late Submission of Grant Applications (NOT-OD-08-027)
- Multiple PI Implementation Update (NOT-OD-06-069) National Institutes of Health
- Development of Assays for High-Throughput Drug Screening (RO1), PA-07-320
- Grants.gov
- Cancer.gov
- Clinical Trials
- Division of Cancer Treatment and Diagnosis
- NIH Public Access Policy
- NIH Support for Conferences
- FDA Office of Orphan Drugs
- FDA Center for Drug Evaluation and Research (CDER)
- Guidelines for Inclusion of Women, Minorities, and Persons with Disabilities in NIH-Supported Conference Grants (NOT-OD-03-066)
- NIH "Welcome Wagon" Letter (Information for New Grantee Organizations)
- Salary Limitation on Grants, Cooperative Agreements and Contracts
- Final NIH Statement on Sharing Research Data
- Reminder to Applicants about Requirement to Submit Complete and Up-to-Date Other Support Information
- HIPAA Privacy Rule (02/05/03)
- Revised NIH Grants Policy Statement (03/01/01)
- CADD Group Chemoinformatics Tools and User Services
- NCI Annual Plan and Budget
- NIH News Flashes
- NCI Research Resources
- NIH Research Grant Funding Mechanisms
- NIH SBIR/STTR
- NCI SBIR/STTR
About the Branch Chief
Dr. Sundar Venkatachalam serves as the chief of PTGB. Sundar earned his Ph.D. in Biochemistry from the Ohio State University, where he studied the molecular mechanisms of DNA damage and repair responses induced by polycyclic aromatic hydrocarbons. As a postdoctoral fellow at the Baylor College of Medicine, he analyzed the role of the p53 haploinsufficiency in tumor susceptibility and aging using genetically engineered mouse models. More…